Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer
Introduction: LncRNAs interact with miRNAs and mRNAs that can have a special expression pattern in a specific cell type. We investigated the specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer (PC). Methods: The mRNAs with significant expression differences were first analyzed...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tabriz University of Medical Sciences
2025-01-01
|
| Series: | BioImpacts |
| Subjects: | |
| Online Access: | https://bi.tbzmed.ac.ir/PDF/bi-15-30510.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850034216588279808 |
|---|---|
| author | Gelareh Vahabzadeh Amirreza Pashapour-Yeganeh Maryam Eini Morad Roudbaraki Ebrahim Esmati Amirhoushang Poorkhani Solmaz Khalighfard Ali Mohammad Alizadeh |
| author_facet | Gelareh Vahabzadeh Amirreza Pashapour-Yeganeh Maryam Eini Morad Roudbaraki Ebrahim Esmati Amirhoushang Poorkhani Solmaz Khalighfard Ali Mohammad Alizadeh |
| author_sort | Gelareh Vahabzadeh |
| collection | DOAJ |
| description | Introduction: LncRNAs interact with miRNAs and mRNAs that can have a special expression pattern in a specific cell type. We investigated the specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer (PC). Methods: The mRNAs with significant expression differences were first analyzed using the GEO and TCGA databases. The lncRNAs and miRNAs were then identified in the miRWalk2, miRmap, OncomiR, miRGator 3.0, miRCancerDB, LncRNA2target, TANRIC, LncRNADisease, Lnc2Cancer v3.0, and LncBase. Seventy subjects, including sixty PC patients classified as local, locally advanced, biochemical relapse, metastatic, and benign groups, as well as ten normal individuals, were then included. Finally, real-time PCR determined the expression of the candidate biomarkers. Results: The bioinformatics analysis detected candidate 6 miRNAs, 6 lncRNAs, and 6 mRNAs in different groups of PC patients. Unlike the significant decrease in candidate tumor suppressors, the expression levels of specific onco-lncRNA, onco-miRNA, and oncogenes exhibited a substantial increase in different groups of the patients compared to the normal group. The expression of lncRNAs, including LINC01128 (P=0.0182), LINC02246 (P<0.0001), and LINC02288 (P<0.0001), LINC00857 (P<0.0001), GNAS-AS1 (P<0.0001), and LINC02371 (P<0.0001), the expression of miRNAs, including miR-217 (P<0.0001), miR-375 (P<0.0001), miR-203a (P<0.0001), miR-876 (P=0.0046), miR-27b (P<0.0001), and miR-152 (P<0.0001), and the expression of oncogenes, including ST14 (P<0.0001), CD24 (P<0.0001), CDH1 (P<0.0001), DSC2 (P<0.0001), TGFB3 (P<0.0001), and MYL2 (P=0.0186) had significant changes at different groups of PC patients. Conclusion: Our results identified promising biomarkers that play a role in specific groups of prostate cancer patients. Detecting specific biomarkers may be an effective strategy for different groups of PC patients. |
| format | Article |
| id | doaj-art-c41f886475b04657b5cf8a0e12b54ce3 |
| institution | DOAJ |
| issn | 2228-5652 2228-5660 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Tabriz University of Medical Sciences |
| record_format | Article |
| series | BioImpacts |
| spelling | doaj-art-c41f886475b04657b5cf8a0e12b54ce32025-08-20T02:57:54ZengTabriz University of Medical SciencesBioImpacts2228-56522228-56602025-01-01151305103051010.34172/bi.30510bi-30510Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancerGelareh Vahabzadeh0Amirreza Pashapour-Yeganeh1Maryam Eini2Morad Roudbaraki3Ebrahim Esmati4Amirhoushang Poorkhani5Solmaz Khalighfard6Ali Mohammad Alizadeh7Razi Drug Research Center, Iran University of Medical Sciences, Tehran, IranCancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, IranCancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, IranLaboratory of Cell Physiology, Inserm U1003, University of Lille, Villeneuve d’Ascq, FranceRadiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, IranIschemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, IranResearch Center for Development of Advanced Technologies, Tehran, IranCancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, IranIntroduction: LncRNAs interact with miRNAs and mRNAs that can have a special expression pattern in a specific cell type. We investigated the specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer (PC). Methods: The mRNAs with significant expression differences were first analyzed using the GEO and TCGA databases. The lncRNAs and miRNAs were then identified in the miRWalk2, miRmap, OncomiR, miRGator 3.0, miRCancerDB, LncRNA2target, TANRIC, LncRNADisease, Lnc2Cancer v3.0, and LncBase. Seventy subjects, including sixty PC patients classified as local, locally advanced, biochemical relapse, metastatic, and benign groups, as well as ten normal individuals, were then included. Finally, real-time PCR determined the expression of the candidate biomarkers. Results: The bioinformatics analysis detected candidate 6 miRNAs, 6 lncRNAs, and 6 mRNAs in different groups of PC patients. Unlike the significant decrease in candidate tumor suppressors, the expression levels of specific onco-lncRNA, onco-miRNA, and oncogenes exhibited a substantial increase in different groups of the patients compared to the normal group. The expression of lncRNAs, including LINC01128 (P=0.0182), LINC02246 (P<0.0001), and LINC02288 (P<0.0001), LINC00857 (P<0.0001), GNAS-AS1 (P<0.0001), and LINC02371 (P<0.0001), the expression of miRNAs, including miR-217 (P<0.0001), miR-375 (P<0.0001), miR-203a (P<0.0001), miR-876 (P=0.0046), miR-27b (P<0.0001), and miR-152 (P<0.0001), and the expression of oncogenes, including ST14 (P<0.0001), CD24 (P<0.0001), CDH1 (P<0.0001), DSC2 (P<0.0001), TGFB3 (P<0.0001), and MYL2 (P=0.0186) had significant changes at different groups of PC patients. Conclusion: Our results identified promising biomarkers that play a role in specific groups of prostate cancer patients. Detecting specific biomarkers may be an effective strategy for different groups of PC patients.https://bi.tbzmed.ac.ir/PDF/bi-15-30510.pdfprostate cancerbiomarkergleasonpsa |
| spellingShingle | Gelareh Vahabzadeh Amirreza Pashapour-Yeganeh Maryam Eini Morad Roudbaraki Ebrahim Esmati Amirhoushang Poorkhani Solmaz Khalighfard Ali Mohammad Alizadeh Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer BioImpacts prostate cancer biomarker gleason psa |
| title | Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer |
| title_full | Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer |
| title_fullStr | Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer |
| title_full_unstemmed | Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer |
| title_short | Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer |
| title_sort | evaluation of specific lncrnas mirnas and mrnas in different groups of prostate cancer |
| topic | prostate cancer biomarker gleason psa |
| url | https://bi.tbzmed.ac.ir/PDF/bi-15-30510.pdf |
| work_keys_str_mv | AT gelarehvahabzadeh evaluationofspecificlncrnasmirnasandmrnasindifferentgroupsofprostatecancer AT amirrezapashapouryeganeh evaluationofspecificlncrnasmirnasandmrnasindifferentgroupsofprostatecancer AT maryameini evaluationofspecificlncrnasmirnasandmrnasindifferentgroupsofprostatecancer AT moradroudbaraki evaluationofspecificlncrnasmirnasandmrnasindifferentgroupsofprostatecancer AT ebrahimesmati evaluationofspecificlncrnasmirnasandmrnasindifferentgroupsofprostatecancer AT amirhoushangpoorkhani evaluationofspecificlncrnasmirnasandmrnasindifferentgroupsofprostatecancer AT solmazkhalighfard evaluationofspecificlncrnasmirnasandmrnasindifferentgroupsofprostatecancer AT alimohammadalizadeh evaluationofspecificlncrnasmirnasandmrnasindifferentgroupsofprostatecancer |